Role of solute carrier transporters in pancreatic cancer: a review
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
25084206
DOI
10.2217/pgs.14.80
Knihovny.cz E-resources
- Keywords
- 5-fluorouracil, SLC transporters, gemcitabine, pancreatic cancer, toxicity, treatment response,
- MeSH
- Adenocarcinoma drug therapy genetics pathology MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Deoxycytidine administration & dosage adverse effects analogs & derivatives MeSH
- Pharmacogenetics * MeSH
- Fluorouracil administration & dosage adverse effects MeSH
- Gemcitabine MeSH
- Humans MeSH
- Membrane Transport Proteins genetics MeSH
- Pancreatic Neoplasms drug therapy genetics pathology MeSH
- Polymorphism, Genetic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Deoxycytidine MeSH
- Fluorouracil MeSH
- Gemcitabine MeSH
- Membrane Transport Proteins MeSH
Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membrane transporters and the potential applications for PDAC therapy with nucleoside analogues are summarized.
References provided by Crossref.org
DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC
SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma
